150 related articles for article (PubMed ID: 24121993)
41. All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma.
Alloussi SH; Alkassar M; Urbschat S; Graf N; Gärtner B
Oncol Rep; 2011 Sep; 26(3):645-9. PubMed ID: 21637921
[TBL] [Abstract][Full Text] [Related]
42. Reovirus uses macropinocytosis-mediated entry and fast axonal transport to infect neurons.
Aravamudhan P; Raghunathan K; Konopka-Anstadt J; Pathak A; Sutherland DM; Carter BD; Dermody TS
PLoS Pathog; 2020 Feb; 16(2):e1008380. PubMed ID: 32109948
[TBL] [Abstract][Full Text] [Related]
43. Reovirus and tumor oncolysis.
Kim M; Chung YH; Johnston RN
J Microbiol; 2007 Jun; 45(3):187-92. PubMed ID: 17618222
[TBL] [Abstract][Full Text] [Related]
44. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.
Adair RA; Roulstone V; Scott KJ; Morgan R; Nuovo GJ; Fuller M; Beirne D; West EJ; Jennings VA; Rose A; Kyula J; Fraser S; Dave R; Anthoney DA; Merrick A; Prestwich R; Aldouri A; Donnelly O; Pandha H; Coffey M; Selby P; Vile R; Toogood G; Harrington K; Melcher AA
Sci Transl Med; 2012 Jun; 4(138):138ra77. PubMed ID: 22700953
[TBL] [Abstract][Full Text] [Related]
45. The 3' sequences required for incorporation of an engineered ssRNA into the Reovirus genome.
Roner MR; Roehr J
Virol J; 2006 Jan; 3():1. PubMed ID: 16390540
[TBL] [Abstract][Full Text] [Related]
46. Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor.
Igase M; Hwang CC; Kambayashi S; Kubo M; Coffey M; Miyama TS; Baba K; Okuda M; Noguchi S; Mizuno T
Can J Vet Res; 2016 Jan; 80(1):21-31. PubMed ID: 26733729
[TBL] [Abstract][Full Text] [Related]
47. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
Shmulevitz M; Lee PW
Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
[TBL] [Abstract][Full Text] [Related]
48. Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release.
Garant KA; Shmulevitz M; Pan L; Daigle RM; Ahn DG; Gujar SA; Lee PW
Oncogene; 2016 Feb; 35(6):771-82. PubMed ID: 25961930
[TBL] [Abstract][Full Text] [Related]
49. Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery.
Kemp V; Dautzenberg IJC; Limpens RW; van den Wollenberg DJM; Hoeben RC
Viruses; 2017 Sep; 9(10):. PubMed ID: 28934149
[TBL] [Abstract][Full Text] [Related]
50. Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.
Kumar V; Giacomantonio MA; Gujar S
Viruses; 2021 Apr; 13(4):. PubMed ID: 33920168
[TBL] [Abstract][Full Text] [Related]
51. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
52. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.
Kelly KR; Espitia CM; Mahalingam D; Oyajobi BO; Coffey M; Giles FJ; Carew JS; Nawrocki ST
Oncogene; 2012 Jun; 31(25):3023-38. PubMed ID: 22002308
[TBL] [Abstract][Full Text] [Related]
53. Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic.
Loken SD; Norman K; Hirasawa K; Nodwell M; Lester WM; Demetrick DJ
Cancer Biol Ther; 2004 Aug; 3(8):734-8. PubMed ID: 15197356
[TBL] [Abstract][Full Text] [Related]
54. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
[TBL] [Abstract][Full Text] [Related]
55. Visualization of viral clearance in the living animal.
Verdin EM; Maratos-Flier E; Kahn CR; Sodoyez JC; Sodoyez-Goffaux F; De Vos CJ; Lynn SP; Fields BN
Science; 1987 Apr; 236(4800):439-42. PubMed ID: 3031817
[TBL] [Abstract][Full Text] [Related]
56. Reovirus Neurotropism and Virulence Are Dictated by Sequences in the Head Domain of the Viral Attachment Protein.
Sutherland DM; Aravamudhan P; Dietrich MH; Stehle T; Dermody TS
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209169
[TBL] [Abstract][Full Text] [Related]
57. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
Villalona-Calero MA; Lam E; Otterson GA; Zhao W; Timmons M; Subramaniam D; Hade EM; Gill GM; Coffey M; Selvaggi G; Bertino E; Chao B; Knopp MV
Cancer; 2016 Mar; 122(6):875-83. PubMed ID: 26709987
[TBL] [Abstract][Full Text] [Related]
58. Reovirus infection in rat lungs as a model to study the pathogenesis of viral pneumonia.
Morin MJ; Warner A; Fields BN
J Virol; 1996 Jan; 70(1):541-8. PubMed ID: 8523567
[TBL] [Abstract][Full Text] [Related]
59. Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus.
Zhao X; Chester C; Rajasekaran N; He Z; Kohrt HE
Mol Cancer Ther; 2016 May; 15(5):767-73. PubMed ID: 27197256
[TBL] [Abstract][Full Text] [Related]
60. Uptake of reovirus serotype 1 by the lungs from the bloodstream is mediated by the viral hemagglutinin.
Verdin EM; Lynn SP; Fields BN; Maratos-Flier E
J Virol; 1988 Feb; 62(2):545-51. PubMed ID: 3336070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
